-
61.发明申请CARBONIC ANHYDRASE INHIBITOR SUSTAINED RELEASE INTRAOCULAR DRUG DELIVERY SYSTEMS 有权碳氢化合物抑制剂持续释放室内药物输送系统公开(公告)号：US20110034448A1
公开(公告)日：2011-02-10
申请号：US11931769
申请日：2007-10-31
IPC分类号： A61K31/433 , A61P27/02 , A61P27/06 , A61P9/10 , A61K31/542 , A61K31/382 , A61P29/00
CPC分类号： A61K9/0051 , A61F9/0008 , A61K48/0041
摘要： Biocompatible intraocular drug delivery systems include a carbonic anhydrase inhibitor therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.
摘要翻译： 生物相容性眼内药物递送系统包括碳酸酐酶抑制剂治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可以保持其三维结构，或者治疗剂可以具有改变的三种。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。
-
62.发明申请Compositions Including Relatively Water Insoluble/Unwettable Drugs And Methods For Using Same 审中-公开包含相对不溶水/不可润湿药物的组合物及其使用方法公开(公告)号：US20090252802A1
公开(公告)日：2009-10-08
申请号：US12295882
申请日：2007-03-22
申请人： James N. Chang , Jane-Guo Shiah
发明人： James N. Chang , Jane-Guo Shiah
CPC分类号： A61K9/146 , A61K9/2054 , A61K9/2077 , A61K31/4164 , A61K31/4166
摘要： Compositions including therapeutic components and surfactant components which enhance the utility of the therapeutic components and methods of using such compositions are provided.
摘要翻译： 提供了包括治疗组分和表面活性剂组分的组合物，其增强治疗组分的用途和使用这些组合物的方法。
-
公开(公告)号：US09161970B2
公开(公告)日：2015-10-20
申请号：US11954602
申请日：2007-12-12
申请人： Ahmet Tezel , Wendy M. Blanda , Patrick M. Hughes , Scott M. Whitcup , James N. Chang , Michael R. Robinson
发明人： Ahmet Tezel , Wendy M. Blanda , Patrick M. Hughes , Scott M. Whitcup , James N. Chang , Michael R. Robinson
IPC分类号： A61K47/36 , A61K47/12 , A61K47/10 , A61L27/10 , A61L27/54 , A61L27/20 , A61K38/48 , A61K9/00
CPC分类号： A61K38/4893 , A61K8/64 , A61K8/66 , A61K8/735 , A61K9/0021 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/42 , A61K2800/48 , A61K2800/54 , A61K2800/91 , A61L27/20 , A61L27/54 , A61L2300/252 , A61L2300/602 , A61L2400/06 , A61Q19/08 , C12N9/6489 , C12Y304/24069 , C08L5/08
摘要： Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
-
公开(公告)号：US09044477B2
公开(公告)日：2015-06-02
申请号：US11954629
申请日：2007-12-12
申请人： Wendy M. Blanda , Roger K. Aoki , Terrence J. Hunt , Patrick M. Hughes , James N. Chang , Scott M. Whitcup , Michael R. Robinson
发明人： Wendy M. Blanda , Roger K. Aoki , Terrence J. Hunt , Patrick M. Hughes , James N. Chang , Scott M. Whitcup , Michael R. Robinson
CPC分类号： A61K38/4893 , A61K9/0019 , A61K9/0024 , A61K47/36 , C12Y304/24069
摘要： Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.
摘要翻译： 用透明质酸载体配制的肉毒杆菌神经毒素，肉毒杆菌毒素在皮下位置的驻留时间增加，肉毒杆菌毒素诱导的并发症或副作用较少。
-
公开(公告)号：US08906861B2
公开(公告)日：2014-12-09
申请号：US12361335
申请日：2009-01-28
CPC分类号： A61K38/13 , A61K9/0019 , A61K9/0048
摘要： A composition is described herein comprising cyclosporin A, polysorbate 80, a polyoxyethylene stearate, and an oil; wherein the composition is an emulsion which is ophthalmically acceptable. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.
摘要翻译： 本文描述了一种组合物，其包含环孢菌素A，聚山梨醇酯80，聚氧乙烯硬脂酸酯和油; 其中所述组合物是眼科可接受的乳液。 使用所述组合物治疗疾病或病症的方法及其相关药物也在本文中公开。
-
公开(公告)号：US08618064B2
公开(公告)日：2013-12-31
申请号：US11897177
申请日：2007-08-28
CPC分类号： A61K38/13 , A61K9/0048 , A61K9/107 , A61K47/02 , A61K47/10 , A61K47/22 , A61K47/32 , A61K47/44
摘要： Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
摘要翻译： 治疗人或动物眼睛的方法包括向人或动物眼睛施用包含水，疏水组分和环孢菌素组分的乳液形式的组合物，其治疗有效量小于0.1重量％ 的组成。 环孢菌素组分与疏水组分的重量比小于0.8。
-
67.发明授权公开(公告)号：US08257730B2
公开(公告)日：2012-09-04
申请号：US11118288
申请日：2005-04-29
申请人： Glenn T. Huang , Thierry Nivaggioli , Lon T. Spada , Hiroshi Sugimoto , Wendy M Blanda , James N. Chang , Orest Olejnik
发明人： Glenn T. Huang , Thierry Nivaggioli , Lon T. Spada , Hiroshi Sugimoto , Wendy M Blanda , James N. Chang , Orest Olejnik
IPC分类号： A61F2/00
CPC分类号： A61K9/0051 , A61K9/0092 , A61K31/573 , A61K31/58 , A61K45/06 , A61K2300/00
摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.
摘要翻译： 生物相容性眼内植入物包括彼此相关的类固醇和聚合物，以促进类固醇进入眼睛大于约两个月的时间。 类固醇可以与可生物降解的聚合物基质相关联，例如两种可生物降解聚合物的基质。 或者，类固醇可以与具有一个或多个开口有效以允许类固醇释放到外部环境中的聚合物涂层相关联。 植入物可以放置在眼睛中以治疗一种或多种眼睛状况。 类固醇从植入物中释放超过约两个月，可能会释放超过几年。
-
公开(公告)号：US08252771B2
公开(公告)日：2012-08-28
申请号：US12023977
申请日：2008-01-31
申请人： Ronald E. Utecht , Kaia L. Kloster , Therese M. Downey , Barbara R. Haberer , Patrick D. Youso , James N. Chang
发明人： Ronald E. Utecht , Kaia L. Kloster , Therese M. Downey , Barbara R. Haberer , Patrick D. Youso , James N. Chang
IPC分类号： A61K31/722 , A61K31/70 , A61K47/48
CPC分类号： A61K47/36 , A61K9/0014 , A61K9/0048 , A61K31/407 , A61K31/5575 , A61K31/573 , A61K47/61 , A61L24/08 , A61L27/20 , A61L2300/404 , A61L2430/16 , C08B37/003 , C08L5/08
摘要： A biomaterial is disclosed having unique properties that make it useful in ocular drug delivery applications, where the drugs selected from the group consisting of a prostaglandin, a prostamide, a non-steroidal anti-inflammatory drug (NSAID), and a corticosteroid, and mixtures, derivatives, salts and esters thereof.
摘要翻译： 公开了具有独特性质的生物材料，其使其可用于眼药物递送应用，其中选自前列腺素，前列腺酰胺，非甾体抗炎药（NSAID）和皮质类固醇的药物和混合物 ，其衍生物，盐和酯。
-
公开(公告)号：US20090155314A1
公开(公告)日：2009-06-18
申请号：US11954602
申请日：2007-12-12
申请人： Ahmet Tezel , Wendy M. Blanda , Patrick M. Hughes , Scott M. Whitcup , James N. Chang , Michael R. Robinson
发明人： Ahmet Tezel , Wendy M. Blanda , Patrick M. Hughes , Scott M. Whitcup , James N. Chang , Michael R. Robinson
CPC分类号： A61K38/4893 , A61K8/64 , A61K8/66 , A61K8/735 , A61K9/0021 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/42 , A61K2800/48 , A61K2800/54 , A61K2800/91 , A61L27/20 , A61L27/54 , A61L2300/252 , A61L2300/602 , A61L2400/06 , A61Q19/08 , C12N9/6489 , C12Y304/24069 , C08L5/08
摘要： Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
摘要翻译： 包含透明质酸和肉毒杆菌毒素的改进的皮肤填充剂制剂。
-
公开(公告)号：US20080145407A1
公开(公告)日：2008-06-19
申请号：US11932373
申请日：2007-10-31
申请人： Glenn T. Huang , Thierry Nivaggioli , Lon T. Spada , Hiroshi Sugimoto , Wendy M. Blanda , James N. Chang , Orest Olejnik
发明人： Glenn T. Huang , Thierry Nivaggioli , Lon T. Spada , Hiroshi Sugimoto , Wendy M. Blanda , James N. Chang , Orest Olejnik
CPC分类号： A61K9/0051 , A61F9/0017 , A61K9/0024 , A61K9/0092 , A61K9/1647 , A61K9/204 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/58 , A61K45/06 , A61K47/593 , A61L27/18 , A61L27/54 , A61L27/58 , A61L31/06 , A61L31/148 , A61L31/16 , A61L2300/222 , A61L2300/436 , A61L2300/45 , A61L2300/604 , A61L2430/16 , A61K2300/00 , C08L67/04
摘要： Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.
摘要翻译： 生物相容性眼内植入物包括类固醇和辅助剂，其中与使用缺乏所述辅助剂的其它相同的植入物相比，辅助剂的存在量足以减轻至少一种副作用的严重性。 类固醇和辅助剂可以存在于相同的眼内植入物或不同的植入物上。 类固醇和辅助剂可以与可生物降解的聚合物基质相结合，例如两种可生物降解的聚合物的基质。 或者，类固醇可以与具有一个或多个开口有效以允许类固醇释放到外部环境中的聚合物涂层相关联。 包含类固醇和辅助剂的植入物可以放置在眼睛中以治疗一种或多种眼部病症，同时减少否则伴随类固醇使用的副作用。
-
-
-
-
-
-
-
-
-
搜索结果
72 条记录 (耗时 0.065 秒)
